Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Evidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (P...

Source: BMC Cancer - February 11, 2019 Category: Cancer & Oncology Authors: Audrey Petitjean, Jayne Smith-Palmer, William Valentine, Bertrand Tehard and Stephan é Roze Tags: Research article Source Type: research